SOM0226, a reprofiled drug for the treatment of TTR amyloidosis, has been presented at the XIIIth International Symposium on Amyloidosis in Groningen, The Netherlands. The product has been recognized as one of the most promising in-coming therapies by the scientific expert community in the field.

SUBCRIBE TO OUR NEWSLETTER

    Name*
    Email*


    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.